The Community Oncology Alliance appoints new officers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE COMMUNITY ONCOLOGY ALLIANCE appointed new officers. Bruce Gould, of Northwest Georgia Oncology Centers in Marietta, Ga., was named president of COA.

Jeff Vacirca, of North Shore Hematology Oncology Associates in East Setauket, N.Y., was named vice-president; Michael Diaz, of Florida Cancer Specialists and Research Institute in Tampa, Fla., was named secretary; and Ricky Newton, of Cancer Specialists of Tidewater in Chesapeake, Va, was named treasurer.

The COA’s immediate past president is Mark Thompson, of The Zangmeister Center in Columbus, Ohio, who will continue to serve as chairman of the COA Payment Reform Task Force and legislative liaison on congressional matters. Past President David Eagle, of Lake Norman Hematology Oncology in Charlotte, N.C., will assume the position of chairman of the Oncology Medical Home Steering Committee.

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login